SCHEMBL6929919

SCHEMBL6929919

NC(=O)NCc1ccncc1

nearest known ligand 0.67

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
RECQL P46063 1/20 0.62
CYP2C9 P11712 1/20 0.60
CYP2C19 P33261 1/20 0.60
ALDH1A1 P00352 3/20 0.56
HSD17B10 Q99714 2/20 0.56
GAA P10253 2/20 0.56
MAPT P10636 2/20 0.56
HTT P42858 2/20 0.54
RAB9A P51151 1/20 0.54
SMN1; SMN2 Q16637 2/20 0.53
P2RX7 Q99572 1/20 0.53
CA2 P00918 1/20 0.53
MAPK1 P28482 2/20 0.51
NAMPT P43490 1/20 0.51
MMP13 P45452 1/20 0.51
LMNA P02545 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Iodide SCHEMBL20524285 0.98 RECQL (0.61) RECQLCYP2C9CYP2C19ALDH1A1HSD17B10
SCHEMBL30559827 0.85 HTT (0.57) ALDH1A1HSD17B10GAAMAPTHTT
Carbamic Acid SCHEMBL31088316 0.84 GAA (0.58) RECQLCYP2C9CYP2C19ALDH1A1HSD17B10
SCHEMBL7789972 0.83 ALDH1A1 (0.56) ALDH1A1HSD17B10GAAMAPTHTT
SCHEMBL21065527 0.83 HTT (0.68) ALDH1A1HSD17B10GAAMAPTHTT
SCHEMBL29783179 0.83 RAB9A (0.73) ALDH1A1HSD17B10GAAMAPTHTT
SCHEMBL11097818 0.82 ALDH1A1 (0.51) RECQLALDH1A1HSD17B10GAAMAPT
SCHEMBL334662 0.81 GAA (0.64) CYP2C9CYP2C19ALDH1A1HSD17B10GAA
SCHEMBL30437853 0.81 GAA (0.64) CYP2C9CYP2C19ALDH1A1HSD17B10GAA
SCHEMBL10405358 0.81 ALDH1A1 (0.58) ALDH1A1HSD17B10GAAMAPTHTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 49 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11918568-B2 Fused ring compound having urea structure Sanford Burnham Prebys Medical Discovery Institute (US) 2024-03-05 US claimed
CN-115109049-A Triazine compound containing aryl urea structure and application thereof 江西科技师范大学 2022-09-27 CN claimed
EP-3638669-A1 SUBSTITUTED PYRROLOPYRIDINE-DERIVATIVES Bayer Pharma Aktiengesellschaft (DE) 2020-04-22 EP claimed
WO-2018228920-A1 SUBSTITUTED PYRROLOPYRIDINE-DERIVATIVES BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2018-12-20 WO claimed
US-20160369208-A1 UREA GELLANT THE PROCTER & GAMBLE COMPANY 2016-12-22 US claimed
EP-1370260-A2 AZOLES AS MALONYL-COA DECARBOXYLASE INHIBITORS USEFUL AS METABOLIC MODULATORS CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2003-12-17 EP claimed
WO-2002066035-A2 AZOLES AS MALONYL-COA DECARBOXYLASE INHIBITORS USEFUL AS METABOLIC MODULATORS CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2002-08-29 WO claimed
US-5096978-A Butadiene polymers having improved scorch delay and fast cure rates; tires; treads MONSANTO COMPANY (US) 1992-03-17 US claimed
EP-0364428-A1 Vulcanizable synthetic rubber compositions cure-activated by substituted ureas Monsanto Company (US) 1990-04-18 EP claimed
US-20250304576-A1 IKK INHIBITORS CANCER RESEARCH TECH LTD (GB) 2025-10-02 US disclosed
US-20250249077-A1 NAMPT FOR WOUND-HEALING AND STIMULATING HAIR GROWTH AND/OR REGROWTH INNOVATIVE SURGICAL REGENERATION HOLDINGS LLC (US) 2025-08-07 US disclosed
CN-115843295-B NAMPT modulators 赛特凯恩蒂克公司 2025-04-15 CN disclosed
US-12240862-B2 Inhibitors of peptidylarginine deiminases GILEAD SCIENCES, INC. (US) 2025-03-04 US disclosed
CN-116354891-B Naphthyl phenyl ether compound, and preparation method and application thereof 河南省锐达医药科技有限公司 2025-01-07 CN disclosed
US-6066641-A PHOSPHODIESTERASES AS MOLECULAR TARGETS FOR ANTI-ASTHMATIC AGENTS EURO-CELTIQUE S.A. (LU) 2000-05-23 US disclosed
EP-0814809-A4 ARYL THIOXANTHINES EURO CELTIQUE SA (LU) 1998-04-01 EP disclosed
EP-0814809-A1 ARYL THIOXANTHINES Euroceltique S.A. (LU) 1998-01-07 EP disclosed
WO-1996018399-A1 ARYL THIOXANTHINES EURO-CELTIQUE, S.A. (LU) 1996-06-20 WO disclosed
US-5096978-A Butadiene polymers having improved scorch delay and fast cure rates; tires; treads MONSANTO COMPANY (US) 1992-03-17 US disclosed
EP-0364428-A1 Vulcanizable synthetic rubber compositions cure-activated by substituted ureas Monsanto Company (US) 1990-04-18 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250304576-A1 IKK INHIBITORS NFKBIA, IKBKE, IKBKB RECQL 380/4885CYP2C9 4023/4885CYP2C19 3875/4885
US-11918568-B2 Fused ring compound having urea structure NAMPT, NME4, ABAT RECQL 1574/4885CYP2C9 3475/4885CYP2C19 3099/4885
US-20160369208-A1 UREA GELLANT UGP2, UGGT1, SLC14A1 RECQL 1897/4885CYP2C9 593/4885CYP2C19 642/4885
US-12240862-B2 Inhibitors of peptidylarginine deiminases PADI4, PADI2, PADI1 RECQL 884/4885CYP2C9 4403/4885CYP2C19 4410/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.